Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Undisclosed
Sponsor : AnovoRx | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Sponsor : AnovoRx | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Premier Research Group | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Premier Research Group | Egetis Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Deal Size : Inapplicable
Deal Type : Inapplicable
Triac Trial II in MCT8 Deficiency Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 24, 2015
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Thyroid Hormone Analog Therapy in MCT8 Deficiency: Triac Trial Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
February 12, 2014
Lead Product(s) : Tiratricol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable